SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
News
20 July 2021: Future Fund: Breakthrough, announced by the Chancellor of the Exchequer at Budget 2021, opens today for applications. This UK-wide programme will deliver £375m of government funding via British Patient Capital, a commercial subsidiary of the British Business Bank.
NHS patients are set to benefit from early access to potentially life-saving new medicines, including cutting-edge gene therapies, thanks to a new Innovative Medicines Fund and £680 million of ringfenced funding, the NHS chief executive has announced today.
Cambridge, UK: 20 July 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge, exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes promoting and leveraging the world class excellence within our network and beyond, by facilitating the right connections.
We will not let hate suppress the success of others. We want to recognise the incredible achievements of the England #football team, and the hard work and strength they've inspired. They should be celebrated.
Everyone, whatever your profession, should have the support and freedom to excel.
We condemn the vicious and racist abuse of all professionals, whether that's online or otherwise, and stand in solidarity with other organisations and leaders who empower success unconditionally.
Today we announce our results for the financial year to 30 April 2021.
The firm has seen a 12% increase in UK revenue to £175.5m and a 23% increase in UK profit to £71m. UK profit per equity partner is 18% up on last year.
Cambridge, UK, 15 July 2021 – PharmEnable, an AI drug discovery company unlocking challenging biological targets, announces that it has entered into a drug discovery collaboration with LifeArc, an independent UK medical research charity, to apply their respective technologies and expertise to discover novel oral antiviral drugs with activity against coronaviruses.
AMSBIO has established an unmatched commercial biorepository and procurement network that includes a large selection of fully characterized and annotated Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks to help streamline your research.
The Biosphere, a specialist lab facility on Newcastle Helix is hosting an online careers event aimed at graduates and postgraduate research students who are looking to make the transition from academia to industry.
The event will see representatives from a range of companies who are based in The Biosphere. They will share their own experiences, personal journey, top tips, and industry insight. They will also showcase some of the exciting job opportunities available to those looking to base themselves in North East.
Today we announce the completion of our permanent office space in the Edward Pavilion building in Liverpool's vibrant and iconic Royal Albert Dock.
The completion of the project follows the signing of a ten-year lease in February 2020 and underlines our long-term commitment to the city and its communities.
Since establishing a presence in Liverpool in November 2018, the firm has built a team of 100+ legal and business experts, and has a growing reputation as an employer of choice for outstanding talent in the region.